Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;6(2):153-62.
doi: 10.4103/0974-8490.129037.

Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis

Krishna Mohan Surapaneni  1 , Mallika Jainu  2
Affiliations

Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis

Krishna Mohan Surapaneni et al. Pharmacognosy Res. 2014 Apr.

Abstract

Background: Non alcoholic steatohepatitis (NASH), severe form of diseases belonging to the spectrum of the Non alcoholic fatty liver disease (NAFLD). It is an asymptomatic disease which leads to fibrosis and finally to cirrhosis, an end stage liver disease.

Objective: To study the effect of pioglitazone, quercetin and hydroxy citric acid on hepatic biomarkers and various biochemical parameters in experimentally induced non alcoholic steatohepatitis (NASH).

Materials and methods: Male Wister rats were divided into 8 groups. The activities of alkaline phosphatase (ALP), aspartate transaminase (AST), alanine transaminase (ALT), lactate dehydrogenase (LDH) and γ-Glutamyl Transferase (GGT) were assayed in serum. The levels of various other biochemical parameters such as serum albumin, total bilirubin, creatinine, urea, uric acid and glucose were also estimated in experimental NASH.

Results: The NASH group produced severe liver injury by significantly increasing the serum levels of ALT, AST, GGT and LDH compared with that of the control. However, the experimental NASH rats treated with pioglitazone, with quercetin and with hydroxy citric acid showed an obvious decrease in ALT, AST, GGT and LDH levels when compared with that of NASH induced group. A significant increase in the levels of albumin, creatinine, urea, uric acid, glucose and total bilirubin was noticed in experimentally induced NASH group (group 2) when compared to rats in control group (group 1).

Conclusion: It could be inferred from this study that, pioglitazone, quercetin and hydroxy citric acid may afford protection to the liver against NASH, as evidenced by the results of this study on the levels of various biochemical parameters such as glucose, urea, uric acid, creatinine and bilirubin. Whereas from the results of hepatic marker enzymes, it is evident that optimal protection was observed after quercetin treatment against experimental NASH whereas pioglitazone and hydroxy citric acid also confers protection to some extent against NASH.

Keywords: Biochemical parameters; experimentally induced NASH; hydroxy citric acid; liver marker enzymes; non alcoholic fatty liver disease; non alcoholic steatohepatitis; pioglitazone; quercetin.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of serum alkaline phosphatase (ALP) in experimental NASH
Figure 2
Figure 2
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of serum alanine transaminase (ALT) in experimental NASH. *P <0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
Figure 3
Figure 3
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of serum aspartate transaminase (AST) in experimental NASH. *P <0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
Figure 4
Figure 4
Effect of pioglitazone, quercetin and hydroxy citric acid on the ratio of serum alanine transaminase (ALT) and aspartate transaminase (AST) in experimental NASH. *P<0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
Figure 5
Figure 5
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of serum lactate dehydrogenase (LDH) in experimental NASH. *P<0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
Figure 6
Figure 6
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of serum gamma glutamyl transferase (GGT) in experimental NASH. *P<0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
Figure 7
Figure 7
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of serum albumin in experimental NASH. *P<0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
Figure 8
Figure 8
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of serum total bilirubin in experimental NASH. *P <0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
Figure 9
Figure 9
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of serum creatinine in experimental NASH. *P <0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
Figure 10
Figure 10
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of serum urea in experimental NASH. *P<0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
Figure 11
Figure 11
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of serum uric acid in experimental NASH. *P <0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
Figure 12
Figure 12
Effect of pioglitazone, quercetin and hydroxy citric acid on the levels of blood glucose in experimental NASH. *P <0.001 compared to control group; aP <0.001 compared to NASH group; bP <0.01 compared to NASH group; cP <0.05 compared to NASH group
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906. - PubMed
    1. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(Suppl 1):S5–10. - PubMed
    1. Cusi K. Non-alcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2009;16:141–9. - PubMed
    1. Kakadiya J, Shah N. Effect of some synthetic and herbel drugs on tumer necrosis factor alpha in renal reperfusion induced renal damage in type 2 diabetic rats. Int J Preclinical Pharm Res. 2011;2:30–7.
    1. Molina MF, Sanchez-Reus I, Iglesias I, Benedi J. Quercetin, a flavonoid antioxidant, prevents and protects against ethanol-induced oxidative stress in mouse liver. Biol Pharm Bull. 2003;26:1398–402. - PubMed

LinkOut - more resources